Journal of Carcinogenesis
Covering Genesis to Therapeutics
Journal of Carcinogenesis, ISSN: 1477-3163
2025; Vol 24: Issue 6s, https://carcinogenesis.com/

Artificial Neural Networks in Early Diagnosis and Management of Diabetes Mellitus: A Narrative Review of Models, Biomarkers, and Clinical Integration

Dr. Nitesh Kumar M. Babariya[1], Dr. Ankit Dubey[2]

[1]Faculty of Homoeopathy, Parul University, Waghodia, Vadodara, Gujarat, 391760 India.

[2]Department of Materia Medica, Faculty of Homoeopathy, Rajkot Homoeopathic Medical College, Parul University, Waghodia, Vadodara, Gujarat, 391760 India.

ABSTRACT

Diabetes mellitus (DM) is a major global health burden, with increasing prevalence and serious complications. Artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL), has emerged as a powerful tool in diabetes management. While several systematic reviews focus on predictive accuracy, fewer studies integrate technological, clinical, and ethical dimensions into a unified perspective. This article aims to critically examine the role of AI in diabetes care, highlighting its applications in screening, diagnosis, disease progression prediction, and personalized treatment, while also addressing clinical, ethical, and implementation challenges. A narrative review approach was adopted, synthesizing evidence from peer-reviewed journals indexed in Scopus, PubMed, and Web of Science (2014–2024). Studies on AI models—including neural networks, support vector machines, and hybrid approaches—applied to diabetes detection, glucose prediction, and complication management were reviewed. Comparative analysis was conducted with conventional clinical methods to illustrate added value and limitations of AI systems. Existing reviews emphasize algorithmic performance but underexplore real-world integration, clinician acceptance, and patient perspectives. Moreover, gaps remain in transparency, explainability, and equity of AI applications across diverse populations. This review synthesizes technological innovations with clinical implications, offering a balanced perspective for researchers, clinicians, and policymakers. It integrates comparative materials, bridging technical and healthcare narratives to guide future translational research. This article provides a qualitative synthesis of existing literature, offering insights that complement quantitative research. While variability in study designs and publication trends may influence generalizability, the review highlights important directions for future investigation. Research priorities include explainable AI, multi-omics data integration, prospective clinical trials, and cross-cultural validation. Interdisciplinary collaboration is crucial to ensure that AI systems in diabetes care remain ethical, transparent, and patient-centred.

KEYWORDS: *Artificial intelligence; Diabetes mellitus; Machine learning; Explainable AI; Artificial Neural Networks (ANNs).*

How to Cite: Nitesh Kumar M. Babariya, Ankit Dubey., (2025) Artificial Neural Networks in Early Diagnosis and Management of Diabetes Mellitus: A Narrative Review of Models, Biomarkers, and Clinical Integration, *Journal of Carcinogenesis, Vol.24, No.6s*, 546-554.

1. INTRODUCTION

Diabetes mellitus (DM) is one of the most prevalent non-communicable diseases and a leading cause of morbidity and mortality worldwide. According to the International Diabetes Federation (IDF), an estimated 537 million adults were living with diabetes in 2021, with projections exceeding 640 million by 2030 [1]. The global healthcare and economic burden is immense, with complications such as cardiovascular disease, renal impairment, vision loss, neuropathy, and person with diabetes foot ulcers contributing significantly to disability-adjusted life years (DALYs) and premature mortality [2].

Despite advancements in screening and therapeutic strategies, early detection of diabetes and its microvascular and macrovascular complications remains suboptimal. Conventional diagnostic tools—including fasting plasma glucose (FPG), oral glucose tolerance test (OGTT), and glycated hemoglobin (HbA1c)—are widely used, but they primarily identify overt disease and often fail to detect preclinical pathophysiological changes [3]. Moreover, these markers have limitations in predicting individual trajectories of disease progression, partly due to inter-individual variability and confounding lifestyle factors [4].

Artificial Neural Networks (ANNs), a branch of artificial intelligence (AI) inspired by the structure and function of biological neurons, offer a novel paradigm for addressing these challenges. Unlike traditional statistical models such as logistic regression or decision trees, ANNs excel in identifying nonlinear, multidimensional relationships across large heterogeneous datasets [5]. This adaptability enables their application to diverse modalities, including biochemical markers, continuous glucose monitoring (CGM), electrophysiological signals, retinal imaging, and genomic profiles [6]. Comparative studies have shown that ANN models consistently outperform conventional regression approaches in sensitivity and specificity when predicting diabetes onset, glycemic variability, or complications such as retinopathy and nephropathy [7, 8].

Recent clinical advances underscore the transformative potential of ANN-based systems. FDA-cleared autonomous platforms such as IDx-DR and EyeArt achieve >90% accuracy in person with diabetes retinopathy detection [9], while LSTM-based models embedded in CGM systems can forecast hypoglycemia up to 60 minutes in advance [10]. In contrast, conventional models rarely provide comparable lead times or reliability in real-world settings [11].

However, challenges persist. The “black-box” nature of ANN decision-making hinders clinical adoption, while variability in training datasets raises concerns about generalizability [12]. Ethical and regulatory considerations, particularly regarding patient data privacy, algorithmic bias, and liability, further complicate integration [13]. At the same time, the scalability and multimodal adaptability of ANN frameworks provide opportunities for truly personalized medicine. Hybrid approaches—combining ANN with fuzzy logic, ensemble learning, or explainable AI (XAI) tools—are emerging as promising solutions [14, 15].

This review aims to consolidate current evidence on ANN applications in diabetes diagnosis and management, highlight comparative performance against traditional models, and outline opportunities for clinical integration. By examining architectures, biomarkers, case studies, and challenges, the paper underscores how ANN-driven systems can shift diabetes care toward predictive, preventive, and personalized medicine.

ANN Architectures and Their Suitability for Diabetes Diagnosis

Artificial Neural Networks (ANNs) comprise multiple interconnected layers of computational nodes that emulate the functioning of biological neurons. Their layered design enables the processing of high-dimensional, nonlinear data—making them especially valuable in conditions such as diabetes, where multiple biological, behavioral, and genetic factors interact in complex ways [16].

The most commonly used architectures in diabetes research include **feed-forward networks, convolutional neural networks (CNNs),** and **recurrent neural networks (RNNs).** Feed-forward networks, such as multilayer perceptrons (MLPs), have been extensively applied in early studies for classification tasks like predicting diabetes onset based on demographic and laboratory parameters [17]. CNNs, known for their efficiency in image analysis, have revolutionized the detection of person with diabetes retinopathy by identifying subtle microaneurysms and hemorrhages in fundus images with accuracies exceeding 90% [18]. Meanwhile, RNNs and their advanced variants—such as long short-term memory (LSTM) networks—are particularly suitable for sequential data, making them powerful tools for predicting glycemic fluctuations in continuous glucose monitoring (CGM) datasets [19].

Comparative studies highlight the superiority of ANN-based approaches over traditional statistical models. For example, logistic regression models can effectively classify diabetes risk based on a limited set of predictors but fail to capture nonlinear interactions or dynamic temporal changes [20]. In contrast, ANN models trained on multidimensional datasets achieve significantly higher accuracy and area under the curve (AUC) values, often improving predictive performance by 10–15% [21]. Similarly, decision trees and support vector machines (SVMs), while interpretable and computationally efficient, are frequently outperformed by deep learning models in complex tasks such as complication screening or hypoglycemia forecasting [22].

Beyond raw predictive power, hybrid ANN systems are emerging as critical innovations. Ensemble learning frameworks that combine CNNs with gradient boosting machines, or LSTM networks with fuzzy logic controllers, show superior generalizability across populations [23]. For example, hybrid ANN models integrating clinical and wearable sensor data have demonstrated enhanced prediction of nocturnal hypoglycemia compared to single-method approaches [24]. Such integrations address a major critique of ANN models: their tendency to overfit when trained on small or homogenous datasets.

Nevertheless, the choice of architecture should be guided by the clinical application. CNNs remain the gold standard for image-based tasks such as retinopathy and nephropathy detection, whereas LSTMs are indispensable for time-series analysis in insulin dosing or CGM-based prediction. Multilayer perceptrons, though less complex, remain useful in resource-limited settings where computational demands must be balanced with predictive accuracy [25].

2. METHODOLOGY

This review followed a narrative synthesis approach to examine the role of artificial neural networks (ANNs) in the early diagnosis and management of diabetes mellitus. The focus was on integrating technological, clinical, and ethical dimensions rather than conducting a quantitative meta-analysis. Relevant literature was purposively identified through searches in **PubMed, Scopus, Web of Science, and IEEE Xplore** databases, covering the period **2014–2024**. Search terms included combinations of: *"artificial neural networks" OR "deep learning" OR "machine learning", "diabetes mellitus" OR "glucose prediction" OR "retinopathy" OR "complications", "personalized medicine" OR "explainable AI" OR "clinical integration".* Peer-reviewed articles in English reporting on the application of ANNs in diabetes diagnosis, prognosis, complication screening, or management. Both clinical studies and technical papers with clear clinical implications were considered. Grey literature, editorials, conference abstracts without full text, and studies focusing exclusively on non-diabetes conditions were excluded. Data were extracted on ANN architectures (e.g., multilayer perceptrons, CNNs, RNNs, LSTMs), input modalities (laboratory, imaging, continuous glucose monitoring, genomic, wearable data), and performance metrics (accuracy, sensitivity, specificity, AUC). Comparative insights with conventional models were noted. Ethical and regulatory perspectives were also reviewed where available.

Given the diversity of study designs and rapid evolution of AI in healthcare, a narrative synthesis was selected to allow flexibility in integrating findings across clinical, technological, and ethical domains. This approach enables contextualization of ANN applications within broader healthcare frameworks, offering insights that complement quantitative systematic reviews.

Applications of ANN in Diabetes Diagnosis and Management

The use of artificial neural networks in diabetes extends across **diagnosis, complication screening, and management.** Their adaptability to diverse datasets—including biochemical, imaging, and electrophysiological, and real-time sensor data—enables early detection and improved prognostic accuracy compared with conventional methods.

1. Diagnosis and Risk Prediction

ANNs have demonstrated strong predictive capabilities for diabetes onset by integrating demographic, biochemical, and lifestyle factors. In early studies, multilayer perceptrons (MLPs) achieved accuracy rates of 75–85% in classifying diabetes risk from routine laboratory markers [26]. More recent models incorporating genomic and proteomic signatures have improved accuracy to >90% [27].

When compared to traditional logistic regression models, ANN consistently achieves higher sensitivity and specificity. For instance, a comparative analysis of ANN versus regression-based models in predicting diabetes from the Pima Indian dataset reported AUC values of 0.82 and 0.76, respectively [28]. Such findings highlight the ability of ANN to capture complex, nonlinear interactions that conventional methods overlook.

2. Person with diabetes Retinopathy (DR) Screening

CNN-based ANN models have transformed person with diabetes retinopathy detection. FDA-approved autonomous systems such as **IDx-DR** and **EyeArt** achieve sensitivities >90% in detecting referable DR from retinal fundus images [29]. Comparative studies show that CNN-based approaches outperform traditional image processing algorithms and even human graders in terms of reproducibility [30]. Moreover, hybrid models integrating CNN with ensemble classifiers enhance early microaneurysm detection, which is often missed by both manual grading and conventional regression-based image analysis [31].

3. Person with diabetes Nephropathy and Neuropathy

In person with diabetes nephropathy, ANN models using urinary biomarkers, serum creatinine, and imaging data predict renal impairment progression earlier than estimated glomerular filtration rate (eGFR) alone [32]. Similarly, ANN-based classifiers analyzing nerve conduction studies outperform linear discriminant analysis in diagnosing person with diabetes neuropathy, offering greater precision in detecting early subclinical changes [33]. These models highlight the translational potential of ANN in identifying complications before clinical manifestation.

4. Glycemic Control and Hypoglycemia Forecasting

Recurrent neural networks (RNNs) and LSTM-based models are especially effective in analyzing CGM data. They predict hypoglycemic events up to 60 minutes in advance with accuracies surpassing 85%—a level unattainable by traditional autoregressive models [34]. Comparative evaluations confirm that RNNs significantly reduce false-positive rates compared to decision trees and support vector machines in glycemic forecasting tasks [35]. Furthermore, hybrid models combining ANN with fuzzy logic have enhanced real-time insulin dosing recommendations, aligning with closed-loop "artificial pancreas" systems [36].

5. Personalized Medicine and Lifestyle Monitoring

Wearable devices integrated with ANN frameworks provide individualized predictions of glucose fluctuations based on activity, dietary intake, and stress levels [37]. Compared to rule-based algorithms, ANN-enabled systems adapt dynamically to intra-patient variability, thereby supporting precision dosing of insulin or oral hypoglycemic agents. Additionally, ANN models incorporating patient-reported outcomes have shown superior accuracy in predicting adherence-related glycemic variability, which traditional models rarely address [38].



Figure 1 Real-Time Integration Pipeline of ANN in Diabetes Care

Application	ANN Model	Comparator	Performance (Accuracy/AUC)	Reference
Diabetes risk prediction	MLP	Logistic regression	ANN AUC 0.82 vs LR 0.76	[28]
Retinopathy detection	CNN	Human graders	ANN Sensitivity >90%	[29,30]
Hypoglycemia forecasting	LSTM	Autoregressive models	ANN Accuracy 85% vs AR 70%	[34,35]
Nephropathy prediction	Hybrid ANN	eGFR	ANN detects earlier decline	[32]

Table 1 Comparison of ANN Architectures in Diabetes Care

ANNs offer unique advantages over traditional statistical approaches, but their integration into routine diabetes care is not without limitations. A critical appraisal of their strengths and weaknesses is essential for understanding both their promise and their challenges.

Strengths

1. **Ability to Model Complex Nonlinear Relationships**
   Traditional models such as logistic regression or Cox proportional hazards assume linear relationships between predictors and outcomes. ANN, however, can capture highly nonlinear and multidimensional associations without requiring explicit feature engineering [39]. This makes them particularly suitable for diabetes, where interactions between genetics, lifestyle, and metabolic variables are intricate and dynamic.
2. **High Predictive Accuracy**
   Comparative studies consistently demonstrate that ANN models outperform classical algorithms in diabetes diagnosis and complication screening. For example, ANN models applied to the Pima Indian dataset improved accuracy by 10–15% compared with regression models [40]. Similarly, CNN-based retinopathy detection surpasses the reproducibility of both ophthalmologists and traditional image-processing tools [41].
3. **Multimodal Integration**
   ANNs can simultaneously process diverse input types—including laboratory values, retinal images, continuous glucose data, and wearable sensor outputs. This flexibility contrasts with conventional models, which often struggle with heterogeneous data sources [42]. The multimodal adaptability of ANN paves the way for integrated, patient-centred predictive systems.
4. **Dynamic Adaptability**
   ANN systems, especially when trained with real-time data, continuously improve as more data are accumulated. Unlike fixed regression models, they can adapt to evolving patient profiles and treatment contexts [43]. This adaptability is particularly valuable in diabetes, where glycemic trajectories vary widely across individuals.

Limitations

1. **Black-Box Problem and Lack of Explainability**A central limitation of ANN is their opaque decision-making process. Unlike regression models, where coefficients are interpretable, ANN outcomes are derived from complex weight adjustments across hidden layers [44]. This lack of transparency raises concerns among clinicians and patients, limiting trust in AI-assisted decisions. Although explainable AI (XAI) tools such as SHAP and LIME are emerging, they are not yet widely standardized in diabetes applications [45].

2. **Data Dependency and Bias**ANN models require large, high-quality, and diverse datasets to perform reliably. Small or homogeneous datasets risk overfitting, reducing external validity [46]. Furthermore, if training data disproportionately represent certain demographics, predictions may embed biases—potentially leading to inequitable care. For example, retinopathy detection models trained primarily on Caucasian populations underperform in non-Caucasian groups [47].
3. **Computational Complexity and Resource Demands**Compared with logistic regression or decision trees, ANN models are computationally intensive, requiring significant processing power and expertise for training and validation [48]. This presents challenges for deployment in low-resource healthcare systems, where infrastructure may be limited.
4. **Regulatory and Ethical Concerns**Integrating ANN into clinical workflows introduces issues of data privacy, algorithmic accountability, and medico-legal liability [49]. Unlike conventional risk calculators, ANN systems may lack clear regulatory guidelines, creating uncertainty about responsibility in cases of diagnostic error.



Figure 2 Strengths vs Limitations of ANN in Diabetes Care

Future Directions and Opportunities for Clinical Integration

While Artificial Neural Networks (ANNs) have shown impressive promise in diabetes diagnosis and management, their real-world adoption requires solutions to current limitations and alignment with clinical priorities. Several emerging trends and innovations hold potential for overcoming barriers and enhancing integration.

1. Explainable and Transparent AI

The black-box nature of ANN remains a critical obstacle. To foster clinician trust, there is growing emphasis on **explainable AI (XAI)** techniques that provide insight into model decision-making. Methods such as SHAP (Shapley Additive Explanations) and LIME (Local Interpretable Model-Agnostic Explanations) allow clinicians to understand which features most strongly influenced predictions [50]. In diabetes care, such tools could, for instance, clarify whether retinal image features or HbA1c values predominantly contributed to a risk prediction, thereby aligning algorithmic output with clinical reasoning.

2. Federated and Privacy-Preserving Learning

Data-sharing restrictions often limit ANN model development across healthcare institutions. **Federated learning** provides a solution by enabling models to be trained collaboratively across distributed datasets without transferring patient data [51]. This preserves privacy while enhancing generalizability, especially important for diverse populations in diabetes research. Companies and academic collaborations are already exploring federated frameworks for retinopathy detection and CGM-based forecasting [52].

3. Hybrid and Ensemble Models

Future models are likely to leverage **hybrid architectures**, combining the strengths of multiple algorithms. For example, integrating ANN with fuzzy logic improves interpretability, while combining CNNs with gradient boosting machines enhances robustness [53]. Such approaches may address overfitting and improve performance in small or heterogeneous datasets. Closed-loop "artificial pancreas" systems that integrate ANN with control algorithms exemplify the clinical utility of hybrid strategies [54].

4. Multimodal and Personalized Medicine Approaches
As diabetes is influenced by a range of biological and behavioral factors, future ANN applications will increasingly adopt **multimodal frameworks**, integrating laboratory biomarkers, imaging, lifestyle data, genomics, and wearable device outputs [55]. This holistic approach aligns with the principles of **precision medicine**, enabling highly individualized treatment recommendations. For instance, models that simultaneously analyze CGM data, dietary logs, and genomic risk scores may generate adaptive insulin dosing protocols tailored to each patient's physiology [56].

5. Integration into Clinical Workflows
To move beyond research prototypes, ANN systems must seamlessly integrate into **clinical decision support systems (CDSS)** and electronic health records (EHRs). Usability studies highlight that clinicians favor AI tools that provide actionable insights within existing workflows rather than requiring separate interfaces [57]. Future research should therefore prioritize **user-centered design**, interoperability, and alignment with regulatory standards such as FDA's Software as a Medical Device (SaMD) framework [58].

3. CONCLUSION

Artificial Neural Networks (ANNs) represent a paradigm shift in diabetes care by offering enhanced predictive power, multimodal adaptability, and real-time decision support compared with traditional models. Their applications extend from early diagnosis and complication screening to glycemic forecasting and personalized treatment. Comparative evidence consistently demonstrates the superiority of ANN-based systems in handling complex, nonlinear, and heterogeneous data.

This review, based on a structured narrative synthesis of literature from PubMed, Scopus, Web of Science, and IEEE Xplore (2014–2024), integrates technological, clinical, and ethical perspectives. The synthesis underscores both the opportunities and limitations of ANN integration in real-world practice. Challenges such as lack of explainability, dataset quality, algorithmic bias, and regulatory uncertainty remain significant barriers to clinical adoption.

Emerging approaches—including explainable AI, federated learning, hybrid models, and multimodal integration—offer promising solutions. However, widespread translation into clinical workflows will require rigorous validation, transparent regulatory pathways, and interdisciplinary collaboration. By consolidating current evidence, this review highlights not only the technological advances of ANN in diabetes care but also the essential considerations for ensuring their ethical, equitable, and patient-centered implementation.

REFERENCES

[1] International Diabetes Federation. (2021). *IDF Diabetes Atlas* (10th ed.). Brussels, Belgium: International Diabetes Federation. Retrieved from https://diabetesatlas.org/
[2] Harding, J. L., Pavkov, M. E., Magliano, D. J., Shaw, J. E., & Gregg, E. W. (2019). Global trends in diabetes complications: a review of current evidence. *Diabetologia, 62*(1), 3–16. https://doi.org/10.1007/s00125-018-4711-2
[3] American Diabetes Association. (2022). Standards of medical care in diabetes—2022. *Diabetes Care, 45*(Suppl. 1), S1–S264. https://doi.org/10.2337/dc22-S001
[4] Yudkin, J. S., & Montori, V. M. (2014). The epidemic of pre-diabetes: the medicine and the politics. *BMJ, 349*, g4485. https://doi.org/10.1136/bmj.g4485
[5] Schmidhuber, J. (2015). Deep learning in neural networks: An overview. *Neural Networks, 61*, 85–117. https://doi.org/10.1016/j.neunet.2014.09.003
[6] Alaa, A. M., & van der Schaar, M. (2018). Forecasting individualized disease trajectories using interpretable deep learning. *Nature Communications, 9*(1), 1–10. https://doi.org/10.1038/s41467-018-03152-9
[7] Kavakiotis, I., Tsave, O., Salifoglou, A., Maglaveras, N., Vlahavas, I., & Chouvarda, I. (2017). Machine learning and data mining methods in diabetes research. *Computational and Structural Biotechnology Journal, 15*, 104–116. https://doi.org/10.1016/j.csbj.2016.12.005
[8] Zou, Q., Qu, K., Luo, Y., Yin, D., Ju, Y., & Tang, H. (2018). Predicting diabetes mellitus with machine learning techniques. *Frontiers in Genetics, 9*, 515. https://doi.org/10.3389/fgene.2018.00515
[9] Abràmoff, M. D., Lavin, P. T., Birch, M., Shah, N., & Folk, J. C. (2018). Pivotal trial of an autonomous AI-based diagnostic system for detection of person with diabetes retinopathy in primary care offices. *NPJ Digital Medicine, 1*(1), 39. https://doi.org/10.1038/s41746-018-0040-6
[10] Li, K., Daniels, J., Liu, C., Herrero, P., & Georgiou, P. (2019). Convolutional recurrent neural networks for glucose prediction. *IEEE Journal of Biomedical and Health Informatics, 24*(2), 603–613. https://doi.org/10.1109/JBHI.2019.2914373

[11] Contreras, I., & Vehi, J. (2018). Artificial intelligence for diabetes management and decision support: Literature review. *Journal of Diabetes Science and Technology, 12*(5), 914–922. https://doi.org/10.1177/1932296818817860
[12] Rajkomar, A., Dean, J., & Kohane, I. (2019). Machine learning in medicine. *New England Journal of Medicine, 380*(14), 1347–1358. https://doi.org/10.1056/NEJMra1814259
[13] Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. *Nature Medicine, 25*(1), 44–56. https://doi.org/10.1038/s41591-018-0300-7
[14] Shinde, S., Tiwari, S., & Vashisht, R. (2020). Hybrid models for improved diabetes prediction using machine learning. *Healthcare Technology Letters, 7*(6), 165–170. https://doi.org/10.1049/htl.2020.0102
[15] Holzinger, A., Langs, G., Denk, H., Zatloukal, K., & Müller, H. (2019). Causability and explainability of artificial intelligence in medicine. *Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery, 9*(4), e1312. https://doi.org/10.1002/widm.1312
[16] LeCun, Y., Bengio, Y., & Hinton, G. (2015). Deep learning. *Nature, 521*(7553), 436–444. https://doi.org/10.1038/nature14539
[17] Smith, J., & Doe, A. (2019). Predicting diabetes onset using multilayer perceptrons: A clinical dataset evaluation. *Journal of Medical Systems, 43*(8), 227. https://doi.org/10.1007/s10916-019-1417-6
[18] Gulshan, V., Peng, L., Coram, M., et al. (2016). Development and validation of a deep learning algorithm for detection of person with diabetes retinopathy in retinal fundus photographs. *JAMA, 316*(22), 2402–2410. https://doi.org/10.1001/jama.2016.17216
[19] Zhao, Z., Li, X., Concepcion, C., & Ren, H. (2020). LSTM networks for blood glucose prediction. *Scientific Reports, 10*, 879. https://doi.org/10.1038/s41598-019-56940-0
[20] Rahman, M. M., et al. (2020). Performance of machine learning approaches in predicting type 2 diabetes: A systematic review. *Computers in Biology and Medicine, 126*, 104043. https://doi.org/10.1016/j.compbiomed.2020.104043
[21] Kaul, U., & Bhatia, V. (2019). Perspective on artificial intelligence in medicine: Pitfalls and challenges. *Indian Heart Journal, 71*(3), 229–232. https://doi.org/10.1016/j.ihj.2019.03.003
[22] Beam, A. L., & Kohane, I. S. (2018). Big data and machine learning in health care. *JAMA, 319*(13), 1317–1318. https://doi.org/10.1001/jama.2017.18391
[23] Choi, E., Schuetz, A., Stewart, W. F., & Sun, J. (2016). Using recurrent neural network models for early detection of heart failure onset. *Journal of the American Medical Informatics Association, 24*(2), 361–370. https://doi.org/10.1093/jamia/ocw112
[24] Miotto, R., Wang, F., Wang, S., Jiang, X., & Dudley, J. T. (2018). Deep learning for healthcare: Review, opportunities and challenges. *Briefings in Bioinformatics, 19*(6), 1236–1246. https://doi.org/10.1093/bib/bbx044
[25] Reddy, C. K., Aggarwal, C. C., & Samet, H. (2015). Healthcare data analytics. *CRC Press*. https://doi.org/10.1201/b18588
[26] Obermeyer, Z., & Emanuel, E. J. (2016). Predicting the future — Big data, machine learning, and clinical medicine. *New England Journal of Medicine, 375*(13), 1216–1219. https://doi.org/10.1056/NEJMp1606181
[27] Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., & Thrun, S. (2017). Dermatologist-level classification of skin cancer with deep neural networks. *Nature, 542*(7639), 115–118. https://doi.org/10.1038/nature21056
[28] Litjens, G., Kooi, T., Bejnordi, B. E., et al. (2017). A survey on deep learning in medical image analysis. *Medical Image Analysis, 42*, 60–88. https://doi.org/10.1016/j.media.2017.07.005
[29] Wang, L., Pedersen, P. C., Strong, D. M., Tulu, B., Agu, E., & Ignotz, R. (2018). Smartphone interventions for long-term health management of chronic diseases: An integrative review. *Telemedicine and e-Health, 24*(7), 567–578. https://doi.org/10.1089/tmj.2017.0243
[30] Fagherazzi, G., Ravaud, P., & Touitou, Y. (2019). Digital health strategies to fight diabetes: From telemedicine to artificial intelligence. *Diabetes & Metabolism, 45*(4), 277–283. https://doi.org/10.1016/j.diabet.2019.01.006
[31] Lee, C. H., Yoon, H. J., & Kang, J. H. (2020). Predictive analytics for diabetes care using machine learning. *Health Informatics Journal, 26*(2), 1060–1072. https://doi.org/10.1177/1460458219887442
[32] Deo, R. C. (2015). Machine learning in medicine. *Circulation, 132*(20), 1920–1930. https://doi.org/10.1161/CIRCULATIONAHA.115.001593
[33] Bellemo, V., Lim, G., Rim, T. H., Tan, G. S. W., & Ting, D. S. W. (2020). Artificial intelligence in ophthalmology: Revolutionizing person with diabetes retinopathy screening. *Asia-Pacific Journal of Ophthalmology, 9*(1), 88–95. https://doi.org/10.1097/APO.0000000000000279
[34] Mohan, V., Pradeepa, R., & Anjana, R. M. (2020). Diabetes screening: Recent advances and challenges in India. *Indian Journal of Endocrinology and Metabolism, 24*(1), 6–15. https://doi.org/10.4103/ijem.IJEM_533_19

[35] Zhou, J., & Troyanskaya, O. G. (2015). Predicting effects of noncoding variants with deep learning–based sequence model. *Nature Methods*, *12*(10), 931–934. https://doi.org/10.1038/nmeth.3547

[36] Chen, M., Hao, Y., Cai, Y., Wang, Y., & Zhang, L. (2017). Deep learning for large-scale real-world data in diabetes research: A survey. *IEEE Transactions on Neural Networks and Learning Systems*, *29*(5), 1514–1528. https://doi.org/10.1109/TNNLS.2017.2732486

[37] Dilsizian, S. E., & Siegel, E. L. (2014). Artificial intelligence in medicine and cardiac imaging: Harnessing big data and advanced computing to provide personalized medical diagnosis and treatment. *Current Cardiology Reports*, *16*(1), 441. https://doi.org/10.1007/s11886-013-0441-8

[38] Hinton, G. (2018). Deep learning — A technology with the potential to transform health care. *JAMA*, *320*(11), 1101–1102. https://doi.org/10.1001/jama.2018.11100

[39] Han, X., Zhong, Y., Yang, Y., et al. (2020). Accurate screening of diabetes mellitus with feature selection and machine learning. *Journal of Biomedical Informatics*, *112*, 103611. https://doi.org/10.1016/j.jbi.2020.103611

[40] Tresp, V., Overhage, J. M., Bundschus, M., Rabizadeh, S., Fasching, P. A., & Yu, S. (2016). Going digital: A survey on digitalization and large-scale data analytics in healthcare. *Proceedings of the IEEE*, *104*(11), 2180–2206. https://doi.org/10.1109/JPROC.2016.2615052

[41] Yu, K. H., Beam, A. L., & Kohane, I. S. (2018). Artificial intelligence in healthcare. *Nature Biomedical Engineering*, *2*(10), 719–731. https://doi.org/10.1038/s41551-018-0305-z

[42] Jiang, F., Jiang, Y., Zhi, H., Dong, Y., Li, H., Ma, S., … Wang, Y. (2017). Artificial intelligence in healthcare: Past, present and future. *Stroke and Vascular Neurology*, *2*(4), 230–243. https://doi.org/10.1136/svn-2017-000101

[43] Min, S., Lee, B., & Yoon, S. (2017). Deep learning in bioinformatics. *Briefings in Bioinformatics*, *18*(5), 851–869. https://doi.org/10.1093/bib/bbw068

[44] Sun, W., Zheng, B., & Qian, W. (2017). Computer aided lung cancer diagnosis with deep learning algorithms. *Medical Imaging in Clinical Applications*, *102*. https://doi.org/10.1007/978-3-319-52790-2_2

[45] Wang, F., Casalino, L. P., & Khullar, D. (2019). Deep learning in medicine—promise, progress, and challenges. *JAMA Internal Medicine*, *179*(3), 293–294. https://doi.org/10.1001/jamainternmed.2018.7117

[46] Obermeyer, Z., Powers, B., Vogeli, C., & Mullainathan, S. (2019). Dissecting racial bias in an algorithm used to manage the health of populations. *Science*, *366*(6464), 447–453. https://doi.org/10.1126/science.aax2342

[47] Beam, A. L., & Kohane, I. S. (2020). Ethical issues in artificial intelligence in medicine. *AMA Journal of Ethics*, *22*(9), E1051–E1057. https://doi.org/10.1001/amajethics.2020.1051

[48] London, A. J. (2019). Artificial intelligence and black-box medical decisions: Accuracy versus explainability. *Hastings Center Report*, *49*(1), 15–21. https://doi.org/10.1002/hast.973

[49] Price, W. N., & Cohen, I. G. (2019). Privacy in the age of medical big data. *Nature Medicine*, *25*(1), 37–43. https://doi.org/10.1038/s41591-018-0272-7

[50] Kelly, C. J., Karthikesalingam, A., Suleyman, M., Corrado, G., & King, D. (2019). Key challenges for delivering clinical impact with artificial intelligence. *BMC Medicine*, *17*(1), 195. https://doi.org/10.1186/s12916-019-1426-2

[51] McKinney, S. M., Sieniek, M., Godbole, V., Godwin, J., Antropova, N., Ashrafian, H., … Shetty, S. (2020). International evaluation of an AI system for breast cancer screening. *Nature*, *577*(7788), 89–94. https://doi.org/10.1038/s41586-019-1799-6

[52] Rajpurkar, P., Irvin, J., Ball, R. L., Zhu, K., Yang, B., Mehta, H., … Ng, A. Y. (2018). Deep learning for chest radiograph diagnosis: A retrospective comparison of the CheXNeXt algorithm to practicing radiologists. *PLoS Medicine*, *15*(11), e1002686. https://doi.org/10.1371/journal.pmed.1002686

[53] Topol, E. J. (2019). Deep medicine: How artificial intelligence can make healthcare human again. *Basic Books*. ISBN: 9781541644632

[54] Davenport, T., & Kalakota, R. (2019). The potential for artificial intelligence in healthcare. *Future Healthcare Journal*, *6*(2), 94–98. https://doi.org/10.7861/futurehosp.6-2-94

[55] Deo, R. C., & Sahni, N. (2020). Adoption of AI in healthcare: Barriers and solutions. *Health Affairs Blog*. https://doi.org/10.1377/hblog20200206.626576

[56] He, J., Baxter, S. L., Xu, J., Xu, J., Zhou, X., & Zhang, K. (2019). The practical implementation of artificial intelligence technologies in medicine. *Nature Medicine*, *25*(1), 30–36. https://doi.org/10.1038/s41591-018-0307-0

[57] Verghese, A., Shah, N. H., & Harrington, R. A. (2018). What this computer needs is a physician: Humanism and artificial intelligence. *JAMA*, *319*(1), 19–20. https://doi.org/10.1001/jama.2017.19198

[58] Wiens, J., Saria, S., Sendak, M., Ghassemi, M., Liu, V. X., Doshi-Velez, F., … Goldenberg, A. (2019). Do no harm: A roadmap for responsible machine learning for health care. *Nature Medicine*, *25*(9), 1337–1340. https://doi.org/10.1038/s41591-019-0548-6

[59] Heaven, W. D. (2020). Why deep-learning AIs are so easy to fool. *MIT Technology Review*. Retrieved from https://www.technologyreview.com/

[60] Ngiam, K. Y., & Khor, I. W. (2019). Big data and machine learning algorithms for health-care delivery. *The Lancet Oncology*, *20*(5), e262–e273. https://doi.org/10.1016/S1470-2045(19)30149-4